Suzhou Ribo Life Science Co Ltd
Suzhou Ribo Life Science Co Ltd is a biotechnology company focused on pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biopharmaceutical products.
Business. Suzhou Ribo Life Science Co Ltd (6938.HK) is a biotechnology and medical research company headquartered in Suzhou. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. It is primarily listed on the Hong Kong Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Suzhou Ribo Life Science Co Ltd (6938.HK) is a biotechnology and medical research company headquartered in Suzhou. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. It is primarily listed on the Hong Kong Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.
### Capital Structure and Liquidity Suzhou Ribo Life Science Co Ltd exhibits a negative total equity of CNY -93.94 million and a debt-to-equity ratio of -5.86, indicating a leveraged capital structure with liabilities exceeding assets. The company holds CNY 406.75 million in cash and equivalents, but this is offset by CNY 550.07 million in long-term debt, resulting in a net cash position of CNY -143.32 million. The current ratio of 0.86 suggests limited short-term liquidity, as current assets fall short of current liabilities.
### Profitability and Returns The company reported a revenue of CNY 148.51 million, with a gross profit of CNY 121.73 million, translating to a gross margin of 81.97%. However, it recorded an operating loss of CNY 263.12 million and a net loss of CNY 278.06 million, indicating significant operational inefficiencies. The return on equity (ROE) is 2.96, while the return on assets (ROA) is -0.33, reflecting poor asset utilization and profitability.
### Segments and Geographic Exposure The company's revenue is not disclosed by segment or geography in the available data. As a result, it is not possible to assess revenue concentration or geographic diversification at this time.
### Growth Trajectory The company's recent financial performance shows a decline in profitability, with a net loss of CNY 278.06 million. Analysts have provided a mean price target of CNY 105.78, with a median of CNY 103.23, suggesting some optimism about future performance. However, the absence of revenue growth data and the current net loss indicate a challenging growth trajectory.
### Risk Factors The company faces medium liquidity risk due to its negative net cash position and high debt levels. The risk of dilution is assessed as low, but the company's negative equity and operating cash flow of CNY -280.69 million suggest potential financial stress. Adjustments in valuation metrics reflect the company's poor financial health.
### Recent Events No specific recent events, such as filings or transcripts, are provided in the available data to inform the company's current status.
- The company has a negative equity position and a high debt-to-equity ratio, indicating significant financial leverage.
- Despite a high gross margin, the company is unprofitable with a large operating and net loss.
- Analysts have provided a range of price targets, suggesting some optimism about future performance.
- The company's liquidity position is weak, with a current ratio below 1 and a negative net cash position.
- There is no available data on revenue segments or geographic exposure, limiting the ability to assess diversification.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Suzhou Ribo Life Science Co Ltd Market data — financials · 2026-05-27
- Suzhou Ribo Life Science Co Ltd Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- Cheng TongExecutive Vice President